Cardiovascular diseases such as coronary heart disease and hypertension have become the number one killer of human beings, and many of them are accompanied by or die from heart failure. Strictly speaking, heart failure is not an independent heart disease, but a complex group of clinical symptoms of various heart diseases such as coronary artery disease, dilated cardiomyopathy, rheumatic heart valve disease and hypertension that have developed to a serious stage, in which coronary artery disease is increasingly becoming the primary cause of heart failure. When these patients develop cardiac insufficiency or heart failure, they cannot be treated singularly according to the original disease. Instead, attention should be paid to the treatment of heart failure because it is extremely dangerous. Due to the aggravation of heart failure, about half of the patients are repeatedly hospitalized within 3 years, and the mortality rate can reach 30% in 2 years and 70% in 6 years, similar to that of malignant tumors. When you see these figures, please do not panic if you are suffering from heart failure. In the past 10 years or so, after repeated exploration and clinical trials, people have found a set of methods to treat heart failure. As long as the standard treatment methods are followed, the long-term prognosis of patients can be greatly improved and the risk of death can be reduced by at least half. What can be done to treat heart failure? Some old patients are so confident that they have become doctors for a long time that they say “cardiotonic, diuretic, vasodilator” and so on. It is true that drugs such as digoxin, diuretics and cardiac pain relievers can improve the patient’s symptoms and make him feel “better”. Many patients are aware of the effects and side effects of these drugs, and can even adjust their own doses according to changes in their condition. But these drugs do not make patients “live longer,” because they do not reduce mortality. In recent years, it has been found that drugs that inhibit neuroendocrine activation in heart failure are the ones that can improve survival, including: angiotensin-converting enzyme inhibitors, beta-blockers, angiotensin II receptor antagonists, and spironolactone. These drugs also improve cardiac function, shrink the enlarged heart, and ultimately improve symptoms. Both at home and abroad, these drugs have been classified as drugs for the standardized treatment of chronic heart failure and should be used adequately as long as they are tolerated by patients. The use of these drugs is even used as a measure of whether or not the treatment is standardized. However, the first impression left by these truly effective drugs is often poor. In particular, beta-blockers have the potential to exacerbate a patient’s symptoms during the start-up phase (typically 6 weeks). As a result, some patients may think that the doctor is “not very good” or “prescribes the wrong medication. Patients may refuse to be seen again or change doctors or hospitals frequently. This is a difficult time for doctors and patients to cooperate and pass together. The “hard” part is the need for constant medication adjustments. The doctor needs to start the medication and gradually increase the dose according to the condition, and the patient needs to closely observe and record the changes in the condition and cooperate with the treatment. The patient needs to closely observe and record the changes in his condition and cooperate with the treatment. Until the medication reaches a sufficient effective dose and the condition is stabilized, stable treatment can be maintained for a long time. Many difficulties can be encountered during this difficult period. Some patients on angiotensin-converting enzyme inhibitors experience dry cough, low blood pressure, and temporary deterioration of renal function; some patients on beta-blockers experience edema and worsening chest tightness. These adverse effects make patients feel that they are not as effective as they were with their previous drugs. And the dose adjustment phase requires a follow-up visit to the hospital every 1-2 weeks, which is not easy for heart failure patients. In addition, the price of these drugs is also higher than the previous cardiac and diuretic drugs, which cost hundreds of dollars per month, making some patients discouraged. It is these drugs that reduce relapse and rehospitalization rates, which can significantly reduce the total long-term medical costs. And the continuation of life is even more difficult to measure in monetary terms. Because of these barriers, it is difficult for general outpatient physicians to administer standardized care to their patients, and many patients with chronic heart failure do not benefit from the latest medical advances. What can be done? The establishment of a heart failure clinic is an effective solution to this problem. Heart failure clinics provide a bridge between doctors and patients. Heart failure clinics are often staffed by experienced clinicians who are familiar with the standard treatment of heart failure and can start medication and gradually increase the dose according to the condition. More importantly, patients are seen by relatively stable heart failure clinicians who have continuity of care, making it easier for doctors to keep track of changes in their condition and facilitate medication adjustments. Practice around the world has shown that standardized treatment through heart failure clinics can improve treatment status and prognosis. According to foreign reports, 34-35% of heart failure patients were discharged from hospital with adequate use of angiotensin-converting enzyme inhibitors, and only 38% were treated in general outpatient clinics after one year, while the utilization rate could be increased to 84% after outpatient heart failure treatment, and the one-year mortality and hospitalization rate was reduced from 42% to 21% in general outpatient clinics. Seriously ill patients and patients who frequently require hospitalization are more likely to benefit from outpatient heart failure treatment and have significantly lower medical costs relative to their condition. Currently, many large and medium-sized hospitals in China have heart failure clinics, through which patients can also be registered and urged to follow up regularly. The heart failure clinics can also register patients and urge them to have regular follow-ups, distribute scientific information and organize health education for patients, so that they can better cooperate with doctors for regular treatment. In short, the heart failure clinic is a second home for heart failure patients. Heart failure is no longer a persistent disease, and the heart failure clinic can give patients a new lease of life.